Griseofulvin, A Novel Host-directed Antimalarial Drug
Funder
National Health and Medical Research Council
Funding Amount
$461,551.00
Summary
This grant is for a Phase II clinical trial to test an FDA & TGA approved drug for a new use as an antimalarial drug. The parasite uses an enzyme from the human RBC to help it replicate & early trials show this drug appears to disrupt the life cycle of the parasite. This Phase II clinical trial will test the drug on human subjects, & if successful, the drug will be a new and novel way in which to treat and prevent malarial infections in humans.
Targeting An Ion Pump In The Malaria Parasite With Multiple Compound Classes
Funder
National Health and Medical Research Council
Funding Amount
$384,686.00
Summary
Large-scale antimalarial drug screening projects have identified three different classes of compound that kill the malaria parasite at extremely low doses and which hold real promise as next-generation antimalarials. Genetic evidence, as well as preliminary data from our own lab, has led us to the hypothesis that all three compound classes exert their antimalarial effect by blocking a molecular ion pump on the parasite surface. The aim of this study is to test this.
The Role Of Duffy And PF4 In The Platelet Killing Of Malaria Parasites.
Funder
National Health and Medical Research Council
Funding Amount
$350,045.00
Summary
Platelets in the blood can kill the Plasmodium parasite, which lives inside red blood cells and causes malaria. Platelets bind parasite-infected red cells and release a molecule that is toxic to the parasite. This project will study why a red cell molecule called Duffy is also needed for this function of platelets. Most Africans carry a gene for Duffy that stops its expression in red cells, and may therefore be more susceptible to malaria because their platelets cannot kill the malaria parasite.
Identifying Novel Antimalarial Targets Using ENU Mutagenesis In The Mouse
Funder
National Health and Medical Research Council
Funding Amount
$760,170.00
Summary
Malaria is estimated to cause 1.2 million deaths per year. The malarial parasite has developed resistance to most drugs and new drugs are needed. We aim to mimic the protective red blood cell diseases common in human populations in malarial endemic areas by identifying host targets that are important in parasite growth.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0989564
Funder
Australian Research Council
Funding Amount
$150,000.00
Summary
State-of-the-art facility for human and animal virus research in the Canberra and surrounding regions. New viral diseases continue to emerge and old viruses re-emerge to pose a threat to human and animal health. To combat these, we propose a dedicated viral disease research facility. The centre will include experienced researchers, biotechnology companies and government agencies working on discovery, prevention and treatment of viral diseases. Forging strong scientific links between these organi ....State-of-the-art facility for human and animal virus research in the Canberra and surrounding regions. New viral diseases continue to emerge and old viruses re-emerge to pose a threat to human and animal health. To combat these, we propose a dedicated viral disease research facility. The centre will include experienced researchers, biotechnology companies and government agencies working on discovery, prevention and treatment of viral diseases. Forging strong scientific links between these organisations will considerably enhance the productivity of these researchers, increase their collaborative and scientific outputs and allow for training of students in the latest technologies. The facility will provide researchers with cutting-edge instrumentation for nationally and internationally important projects that would benefit human health.Read moreRead less
Uncovering The Basis Of Inflammatory And Immunodeficiency Diseases
Funder
National Health and Medical Research Council
Funding Amount
$15,718,075.00
Summary
A world-class team from 3 institutions, spanning disciplines of clinical and experimental immunology, therapeutics, signalling and genetics, will identify how immune and inflammatory responses are controlled in both health and disease. The major outcomes of this work will be the generation of new knowledge, concepts and approaches to diagnose, prevent and treat the major human health problems of autoimmune diseases, inflammation, allergy and immunodeficiency.
Special Research Initiatives - Grant ID: SR0354888
Funder
Australian Research Council
Funding Amount
$30,000.00
Summary
Australian Research Council Research Network for Parasitology. Parasites are a major cause of death and suffering in humans and animals throughout the world. The ARC Research Network for Parasitology aims to bring together Australia's finest researchers and establish a world class environment and web of facilities that attracts and retains the most talented young investigators and places Australia in a strong position to deal with current and future parasitological threats. The Network will focu ....Australian Research Council Research Network for Parasitology. Parasites are a major cause of death and suffering in humans and animals throughout the world. The ARC Research Network for Parasitology aims to bring together Australia's finest researchers and establish a world class environment and web of facilities that attracts and retains the most talented young investigators and places Australia in a strong position to deal with current and future parasitological threats. The Network will focus and enhance Australia's fundamental, strategic and applied parasitology research capabilities to :
(1) develop new approaches to vaccination;
(2) identify novel drug targets; and
(3) ensure the sustainability of wildlife and ecosystem health.
Read moreRead less
ARC/NHMRC Research Network for Parasitology. The ARC Network for Parasitology will focus and coordinate Australia's world class fundamental, strategic and applied parasitology research. This targeted approach will raise Australia's standing in the field, assist in the community's understanding of parasitology and biosecurity and maintain and improve Australia's capacity for keeping its stock, crops, wildlife and people disease-free. On an international scale, the Network will work with other cou ....ARC/NHMRC Research Network for Parasitology. The ARC Network for Parasitology will focus and coordinate Australia's world class fundamental, strategic and applied parasitology research. This targeted approach will raise Australia's standing in the field, assist in the community's understanding of parasitology and biosecurity and maintain and improve Australia's capacity for keeping its stock, crops, wildlife and people disease-free. On an international scale, the Network will work with other countries to develop new technologies for the detection and eradication of parasites. This emphasis will not only protect Australia's borders but will assist our near neighbours and lead to the development of technologies with an economic benefit to Australia.
Read moreRead less
Towards A Chlamydia Vaccine For Males: The Key Role Of Mucosal IgA
Funder
National Health and Medical Research Council
Funding Amount
$418,978.00
Summary
Genital Chlamydia infections are the most common sexually transmitted infection in Australia with annual health costs of 90-160 million dollars. Infection rates in 15-29 olds are increasing at 15-20% per year in both females and males. Antibiotics are currently the treatment of choice, however antibiotic resistance is increasing and most infections are asymptomatic and not treated in the absence of screening programs. This project aims to develop a Chlamydia vaccine tailored to protect males .
Bioreactors for manufacture of human platelets. Blood cell transfusion is a critical part of medicine that is supported by volunteer donors. Unfortunately, the demand for blood cells for transfusion far outstrips supply and therefore new strategies are required for manufacture of blood cells. This project will lead to the development of technology for manufacture of human platelets from stem cells. The systems devised will be applicable to a broad range of other blood cell types.